

Please Type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

JUL 06 2001

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 18

### Complete if Known

Application Number	09/804,111
Filing Date	March 12, 2001
First Named Inventor	Nongnuch Inpanbutr
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	06204-00102

RECEIVED

JUL 11 2001

TECH CENTER 1600/2900

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
M <sup>2</sup>	AA	4,022,891		Takeshita et al.	May 10, 1977	
	AB	4,341,774		Aoki et al.	July 27, 1982	
	AC	4,364,941		Kiyoki et al.	Dec. 21, 1982	
	AD	4,442,093		Maeda et al.	April 10, 1984	
	AE	4,948,789		Slatopolsky	August 14, 1990	
	AF	5,043,170		Borenstein et al.	August 27, 1991	
	AG	5,063,221		Nishii et al.	Nov. 5, 1991	
	AH	5,087,619		Baggiolini, deceased et al.	Feb. 11, 1992	
	AI	5,145,846		Baggiolini, deceased et al.	Sep. 8, 1992	
	AJ	5,183,815		Saari et al.	Feb. 2, 1993	
	AK	5,250,523		DeLuca et al.	Oct. 5, 1993	
	AL	5,597,815		DeLuca et al.	Jan. 28, 1997	
	AM	5,602,116		Knutson et al.	Feb. 11, 1997	
	AN	5,707,980		Knutson et al.	Jan. 13, 1998	
	AO	5,861,386		Knutson et al.	Jan. 19, 1999	
	AP	5,869,473		Knutson et al.	Feb. 9, 1999	
	AQ	5,972,917		Bishop et al.	Oct. 26, 1999	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	FA							
	FB							
	FC							
	FD							
	FE							
	FF							
	FG							
	FH							
	FI							

Examiner Signature

*[Handwritten Signature]*

Date Considered:

02/21/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/804,111	
			Filing Date	March 12, 2001	
			First Named Inventor	Nongnuch Inpanbutr	
			Group Art Unit	1645	
Examiner Name					
Sheet	2	of	18	Attorney Docket Number	06204-00102

RECEIVED  
JUL 11 2001  
TECH CENTER 1600/2900

**OTHER PRIOR ART - - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the items (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MB	OA	YU, J.; PAPAVALIOU, V; RHIM, J; GOLTZMAN, D; KREMER, R: "Vitamin D Analogs: New Therapeutic Agents For The Treatment Of Squamous Cancer And Its Associated Hypercalcemia," <i>Anticancer Drugs</i> 1995 Feb;6(1):101-8 <i>abstract only</i>	
MB	OB	WERKMEISTER, JR; MERRYMAN, JI; MCCAULEY, L; HORTON, JE; CAPEN, CC; ROSOL, TJ: "Parathyroid Hormone-related Protein Production By Normal Human Keratinocytes In Vitro," <i>Exp Cell Res</i> 1993 Sep;208(1):68-74 <i>abstract only</i>	
MB	OC	MERRYMAN, JI; CAPEN, CC; MCCAULEY, LK; WERKMEISTER, JR; SUTER, MM; ROSOL, TJ: "Regulation Of Parathyroid Hormone-related Protein Production By A Squamous Carcinoma Cell Line In Vitro," <i>Lab Invest</i> 1993 Sep;69(3):347-54 <i>abstract only</i>	
MB	OD	WANG, X; CHEN, X.; AKHTER, J; MORRIS, DL: "The In Vitro Effect Of Vitamin D3 Analogue EB-1089 On A Human prostate Cancer Cell Line (PC-3)," <i>British Journal Of Urology</i> (1997), 80, 260-262	
MB	OE	COLSTON, KW; JAMES, SY; OFORI-KURAGU, EA; BINDERUP, L; GRANT, AG: "Vitamin D Receptors And Anti-proliferative Effects Of Vitamin D Derivatives In Human Pancreatic Carcinoma Cells In Vivo And In Vitro," <i>British Journal of Cancer</i> (1997)76(8), 1017-1020	
MB	OF	BERG, JENS P.; LIANE, KJELLAUG, M.; BJØRHØVDE, SIRI B.; BJØRO, TRINE; TORJESSEN, PETER A.; HAUG, EGIL: "Vitamin D Receptor Binding And Biological Effects Of Cholecalciferol Analogues In Rat Thyroid Cells," <i>J. Steroid Biochem.Molec.Biol.</i> Vol. 50	
MB	OG	SKOWRONSKI, ROMAN J.; PEEHL, DONNA M.; FELDMAN, DAVID: "Actions Of Vitamin D <sub>3</sub> Analogs On Human Prostate Cancer Cell Lines: Comparison With 1,25-Dihydroxyvitamin D <sub>3</sub> ," <i>Endocrinology</i> 1995 by The Endocrine Society	

Examiner Signature		Date Considered:	02/21/01
--------------------	--	------------------	----------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →

PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/804,111		
		Filing Date	March 12, 2001		
		First Named Inventor	Nongnuch Inpanbutr		
		Group Art Unit	1645		
Examiner Name					
Sheet	3	of	18	Attorney Docket Number	06204-00102

MS	OH	KOLI, KATRI; KESKI-OJA, JORMA: "1,25-Dihydroxyvitamin D <sub>3</sub> Enhances The Expression Of Transforming Growth Factor B1 And Its Latent Form Binding Protein In cultured Breast Carcinoma Cells," <i>Cancer Research</i> 55,1540-1546, April 1, 1995	
MP	OI	MOORE, THEODORE B.; KOEFFLER, H. PHILLIP; YAMASHIRO, JOYCE M.; WADA, RANDAL K.: "Vitamin D <sub>3</sub> Analogs Inhibit Growth And Induce differentiation In LA-N-5 Human Neuroblastoma Cells," <i>Clin.Exp. Metastasis</i> , 1996, 14, 239-245	
MS	OJ	ZHOU, JIAN-YUAN; NORMAN, ANTHONY W.; CHEN, DAN-LIN; SUN, GUO-WEN; USKOKOVIC, MILAN: "1-25-Dihydroxy-16-ene-23-yne-vitamin D <sub>3</sub> Prolongs Survival Time Of Leukemic Mice," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 3939-3932 May 1990 Medical Sciences	
MS	OK	ZHOU, JIAN-YUAN; NORMAN, A.W.; LUBVERT, M.; COLLINS, E.D.; USKOKOVIC, M.R.; KOEFFLER, H.P.: "Novel Vitamin D Analogs That Modulate Leukemic Cell Growth And Differentiation With Little Effect On Either Intestinal Calcium Absorption Or Bone Calcium Mobilization," <i>Blood</i> , Vol. 74, No. 1(July), 1989: pp 82-93	
MS	OL	NORMAN, ANTHONY W.; ZHOU, J.Y.; HENRY, HELEN L.; USKOKOVIC, MILAN R.; KOEFFLER, H. PHILLIP: "Structure-Function Studies On Analogues Of 1 $\alpha$ , 25-Dihydroxyvitamin D <sub>3</sub> : Differential Effects on Leukemic Cell Growth, Differentiation, and Intestinal Calcium Absorption," <i>Cancer Research</i> 50,6857-6864, November 1, 1990	
MS	OM	NORMAN, AW; SERGEEV, IN; BISHOP, JE; OKAMURA, WH: "Selective Biological Response By Target Organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D <sub>3</sub> :and Two Analogues," <i>Cancer Res (United States)</i> , Sep1, 1993, 53 (17) p3935-42 <i>abstract only</i>	
MS	ON	SHAMS, G; ROMSTEDT, KJ; GERHARDT, MA; HARROLD, MW; MILLER, DD; FELLER, DR: "Pharmacological Evaluation of the Beta-adrenoceptor Agonist and Thromboxane Receptor Blocking Properties of 1-benzyl Substituted Trimetoquinol Analogues," <i>J Pharmacol (Netherlands)</i> , Aug 2, 1990, 184 (1) p21-31 <i>abstract only</i>	


Examiner Signature		Date Considered:	02/21/02
--------------------	--	------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/804,111
				Filing Dat	March 12, 2001
				First Named Inventor	Nongnuch Inpanbutr
				Group Art Unit	1645
				Examiner Name	
Sheet	4	of	18	Attorney Docket Number	06204-00102

MS	OO	PRESSOVA, M; SMRT, J: "Lipid Derivatives of (2'-5') Oligo A," <i>Nucleic Acids Symp Ser (England)</i> , 1987, (18) P101-4 <i>abstract only</i>	
	OP	TSE, FL; CHRISTIANO, JR; TALBOT, KC: "Relative Absorption of Tryptophan Ethyl Ester Amide Derivatives With Various Fatty Acid Chains In The Dog," <i>J Pharm Pharmacol (England)</i> , Sep 1984, 36(9) p633-6 <i>abstract only</i>	
	OQ	BIKOLICS, K; BIEGLMAYER, C; SPONA, J; SEPRODI, J; TEPLAN, I: "Inhibition of LH-release By Synthetic Analogues of LH-RH in Rat Pituitary Cell Culture," <i>Peptides (United States)</i> , Spring 1981, 2(1) p65-73 <i>abstract only</i>	
	OR	GUDKOV, ND; STOLOVITSKII, IUM; EVSTIGNEEV, VB: "Impulse Photoconductivity of Solutions of Chlorophyll and its Analogs," <i>Biofizika (USSR)</i> , Mar-Apr 1975, 20(2) p214-8 <i>abstract only</i>	
	OS	LAN, SJ; DEAN, AV; WALKER, BD; SCHREIBER, EC: "Metabolism of a Benzothiazine Compound by the Intact Rat, Isolated Perfused Rat Liver, and Rat-liver Microsomes," <i>Xenobiotica (England)</i> , Mar 1976,6(3) p171-83 <i>abstract only</i>	
	OT	POIRIER, MA; BLACK, DB; LOVERING, EG: "Formation of Alkyl Carbamates From Glyburide: Potential for Overestimation in the BP Glibenclamide (Glyburide) Foreign Substances Test," <i>Can. J. Pharm. Sci.</i> ; VOL 15 ISS, Jan 1980, P8-9 <i>abstract only</i>	
	OU	BOWMAN, JC; BEROZA, M; HARDING, JA: "Determination of Phorate and Five of Its Metabolites in Corn," <i>J. Agr. Food Chem.</i> ; 17(1), 138-42, 1969 <i>abstract only</i>	
	OV	<del>HUANG, W; SHOBANA, S; ANDERSEN, OS; GREATHOUSE, DV; KOEPPE, RE: "Double-stranded Channels Are Formed by Gramicidin Analog, V-9GLW," <i>Biophysical Journal</i>, 72 (2 Part 2):pA395 1997</del>	
MB	OW	UCHIYAMA, MINORU; MURAKAMI, TOSHIKI: "Effects of AVT and Vascular Antagonists on Kidney function and Smooth Muscle Contraction in the River Lamprey, <i>Lampetra Japonica</i> ," <i>Comparative Biochemistry and Physiology A Comparative Physiology</i> , 107 (3):p493-499 1994 <i>abstract only</i>	


Examiner Signature	<i>[Signature]</i>	Date Considered:	02/21/02
--------------------	--------------------	------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/804,111	
			Filing Date	March 12, 2001	
			First Named Inventor	Nongnuch Inpanbutr	
			Group Art Unit	1645	
			Examiner Name		
Sheet	5	of	18	Attorney Docket Number	06204-00102

M/O	OX	MANHI, FM; ABDEL-FATTAH, AM: "Reactions with 6-substituted-2-thiouracil-5-carbonitriles. Synthesis of Tetrazolo (1,5-c) and Ditetrazolo (1, 5-a: 1, 5-c) Pyrimidines," <i>Egyptian Journal of Pharmaceutical Sciences</i> , 33 (5-6):p825-838, 1992 (1993) <i>abstract only</i>	
	OY	COMPTON, DR; JOHNSON, MR; MELVIN, LS; MARTIN, BR: "Pharmacological Profile of a Series of Bicyclic Cannabinoid Analogs Classification as Cannabimimetic Agents," <i>J Pharmacol Exp Ther</i> 260 (1). 1992. 201-209 <i>abstract only</i>	
	OZ	AHMAD, MS; HUSAIN, SR; HUSAIN M.; CHOUDHRY, ZH: "On The synthesis of Some More Steroidal Tetrazoles," <i>Indian J Chem Sect B Org Chem Incl Med Chem</i> 16 (7). 1978 559-562 <i>abstract only</i>	
	OAA	CHU, CK; REICHMAN, U; WATANABE, KA; FOX, JJ: "Nucleosides Part 109 2 Deoxy-PSI ISO Cytidine 2 Deoxy-PSI Uridine and 2 Deoxy-1-Methyl-PSI Uridine Isosteres of Deoxy Cytidine Deoxy Uridine and Thymidine," <i>J Heterocyclic Chemistry</i> , 14 (6). 1977 1119-1121 <i>abstract only</i>	
	OAB	CHINN, MK; MYBURGH, KH; PHAM, T; FRANKSSKIBA, K; COOKE, R.: "The Effect of Polyethylene Glycol on the Mechanics and ATPase Activity of Active Muscle Fibers," <i>Biophysical Journal</i> , 2000, V78, N2 (FEB), P927-939 <i>abstract only</i>	
	OAC	KUMAR, V; COULSELL, E; OBER, B; HUBBARD, G; SERCARZ, E; WARD, ES: "Recombinant T Cell Receptor Molecules Can Prevent And Reverse Experimental Autoimmune Encephalomyelitis - Dose Effects and Involvement of Both CD4 and CD8 T Cells," <i>Journal Of Immunology</i> , 1997, V159, N10 (Nov 15), p5150-5156 <i>abstract only</i>	
	OAD	LEFLOCH, C; HENDERSON, RA; HITCHCOCK, PB; HUGHES, DL; JANAS, Z; RICHARDS, RL; SOBOTA, P; SZAFERT, S: "Reactions of Substituted Hydrazines With Vanadium(iii) Compounds - Crystal-Structures of [NH(2)ME(2)](2)[(VCL3)(2)(MU-NNME(2)) (3)], [V(OC6H3PR2I-2,6)(3) (NH(2)NME(2)) (2)], AND [V(OC6H3PR2I-2,6) (3) (NH(2)NMEPH)2]," <i>Journal of the Chemical Society-Dalton Transactions</i> , 1996, N13 (JUL 7), P2755-2762 <i>abstract only</i>	
NB	OAE	BHAUMIK, A; DONGARE, MK; KUMAR, R: "Synthesis of MTW-Type Microporous Material and Its Vanadium-Silicate Analog Using a New Diquaternary Ammonium Cation as a Template," <i>Microporous Materials</i> , 1995, V5, N3 (Nov), P173-178 <i>abstract only</i>	

Examiner Signature		Date Considered: 02/21/02
--------------------	--	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/804,111
		Filing Date	March 12, 2001
		First Named Inventor	Nongnuch Inpanbutr
		Group Art Unit	1645
		Examiner Name	
Sheet 6 of 18	Attorney Docket Number	06204-00102	

ms	OAF	REHDER, D: "Structure and Function of Vanadium Compounds in Living Organisms," <i>Biometals</i> , 1992, V5, N1 (SPR), P3-12 *	
	OAG	KABANOS, TA; WHITE, AJP; WILLIAMS, DJ; WOOLLINS, JD: "Synthesis and X-ray Structures of BIS (3, 5-DI-TERT-BUTYLCATECHOLATO) (PHENANTHROLINE) Vanadium (IV) and its Vanadium(V) Analog [V(DTBC) 2 (PHEN)] [SBF6]," <i>Journal of the Chemical Society-Chemical Communications</i> , 1992, N1 (JAN 1), P17-18 *	
	OAH	TOVERUD, SU; ANDERSON, JJB; GARNER, SC: "Vitamin D," <i>Food Science &amp; Technology</i> , 1995 *	
	OAI	NORMAN, AW; SERGEEV, IN; BISHOP, JE; OKAMURA, WH: "Selective Biological Response by Target Organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D <sub>3</sub> and Two Analogues," <i>Cancer Research</i> , (United States) 1993, 53/17 (3935-3942) *	
	OAJ	VAN DEN BEMD, G-JCM; POLS, HAP; BIRKENHAGER, JC; KLEINEKOORT, WMC; VAN LEEUWEN, JPTM: "IMSWorld R&D Focus, June 28, 1999" *	
	OAK	EL ABDAMI, K; PAPAVALIOU, V; RABBANI, SA; RHIM, JS; GOLTZMAN, D; DREMER, R: "Reversal of Hypercalcemia with the Vitamin D Analogue EB1089 In A Human Model of Squamous Cancer," <i>Cancer Research</i> , (United States), Jul 15, 1999, 59 (14) p3325-8 *	
	OAL	KOSZEWSKI, JN; REINHARDT, TA; HORST, RL: "Differential Effects of 20-3pi Vitamin D Analogs on the Vitamin D Receptor Homodimer," <i>J Bone Miner Res</i> (United States) Apr 1999, 14 (4) p509-17 *	
	OAM	KOSHIZUKA, K; KOIKE, M; ASOU, H; CHO, SK; STEPHEN, T; RUDE, RK; BINDERUP, L; USKOKOVIC, M; KOEFFLER, HP: "Combined Effect of Vitamin D <sub>3</sub> Analogs and Paclitaxel on the Growth of MCF-7 Breast Cancer Cells In Vivo," <i>Breast Cancer Res Treat</i> (Netherlands), Jan 1999, 53 (2) p113-20 *	
ms	OAN	KOSHIZUKA, K; KUBOTA, T; SAID, J; KOIKE, M; BINDERUP, L; USKOKOVIC, M; KOEFFLER, HP: "Combination Therapy of a Vitamin D <sub>3</sub> Analog and All-Trans-Retinoic Acid: Effect on Human Breast Cancer in Nude Mice" <i>Anticancer Res</i> (Greece), Jan-Feb 1999, 19 (1A) p519-24 *	

\* only abstracts have been considered

Examiner Signature	<i>[Signature]</i>	Date Considered:	02/21/02
--------------------	--------------------	------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/804,111
Filing Date	March 12, 2001
First Named Inventor	Nongnuch Inpanbutr
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	06204-00102

RECEIVED

JUL 11 2001

TECH CENTER 1600/2900

Sheet 7 of 18

MB	OAQ	LOKESHWAR, BL; SCHWARTZ, GG; SELZER, MG; BURNSTEIN, KL; ZHUANG, SH; BLOCK, NL; BINDERUP, L: "Inhibition of Prostate Cancer Metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089," <i>Cancer Epidemiol Biomarkers Prev</i> (United States), Mar 1999, 8(3) p241-8 *	
	OAP	NICKERSON, T; HUYNH, H: "Vitamin D Analogue EB1089-Induced Prostate Regression is Associated With Increased Gene Expression of Insulin-like Growth Factor Binding Proteins," <i>J Endocrinol</i> (England), Feb. 1999, 160(2) p223-9 *	
	OAQ	JAMES, SY; MERCER, E; BRADY, M; BINDERUP, L; COLSTON, KW: "A Synthetic Analogue of Vitamin D, Induces Apoptosis in Breast Cancer Cells In Vivo and In Vitro," <i>Br J Pharmacol</i> (England), Nov 1998, 125 (5) p953-62 *	
	OAR	MATHIASSEN, IS; COLSTON, KW; BINDERUP, L: "A Novel Vitamin D Analogue, Has Strong Antiproliferative and Differentiation Inducing Effects On Cancer Cells," <i>J Steroid Biochem Mol Biol</i> (England), Sep 1993, 46(3) p365-71 *	
	OAS	SOMJAN, D.; WAISMAN, A; WEISMAN, J; KAYE, AM: "Nonhypercalcemic Analogs of Vitamin D Stimulate Creatine Kinase B Activity in Osteoblast-like ROS 17/2.8 Cells and Up-regulate Their Responsiveness to Estrogens," <i>Steroids</i> (United States) May-June 1998, 63 (5-6) P340-3 *	
	OAT	VANWEELDEN, K.; FLANAGAN, L; BINDERUP, L; TENNISWOOD, M; WELSH, J: "Apoptotic Regression of MCF-7 Xenografts in Nude Mice Treated with the Vitamin D <sub>3</sub> Analog," <i>Endocrinology</i> (United States) April, 1998, 139(4) -2102-10 *	
	OAU	HANSEN, CM; MAENPAA, PH: "A Novel Vitamin D Analog With Strong Antiproliferative and Differentiation-inducing Effects on Target Cells," <i>Biochem Pharmacol</i> (England), Dec 1 1997, 54(11) p1173-9 *	
MB	OAV	DANIELSSON, C; MATHIASSEN, IS; JAMES, SY; NAYERI, S; BRETTING, C; HANSEN, CM; COLSTON, KW; CARLBERG, C: "Sensitive Induction of Apoptosis in Breast Cancer Cells by a Novel 1,25-dihydroxyvitamin D <sub>3</sub> ," <i>J Cell Biochem</i> (United States), Sep 15 1997, 66(4) p552-62 *	

\* only abstract have been considered


Examiner Signature:	Date Considered: 02/21/02
---------------------	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance, and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/804,111	
			Filing Date	March 12, 2001	
			First Named Inventor	Nongnuch Inpanbutr	
			Group Art Unit	1645	
			Examiner Name		
Sheet	8	of	18	Attorney Docket Number	06204-00102

Wb	OAW	COLSTON, KW; JAMES, SY; OFORI-KURAGU, EA; BINDERUP, L; GRANT, AG: "Vitamin D Receptors and Anti-proliferative Effects of Vitamin D Derivatives in Human pancreatic Carcinoma Cells In Vivo and In Vitro," <i>Br J Cancer</i> (Scotland) 1997, 76(8) p1017-20	*
	OAX	SCHRADER, M; KAHLEN, JP; CARLBERG, C: "Functional Characterization of a Novel Type of 1 Alpha, 25-dihydroxyvitamin D <sub>3</sub> Response Element Identified in the Mouse C-fos Promoter," <i>Biochem Biophys Res Commun</i> (United States) Jan 23 1997, 230(3) p646-51	*
	OAY	ZUGMAIER, G; JAGER, R; GRAGE, B; GOTTARDIS, MM; HAVEMANN, K; KNABBLE, C: "Growth-inhibitory Effects of Vitamin D Analogues and Retinoids on Human Pancreatic Cancer Cells," <i>Br J Cancer</i> (Scotland), Jun 1996, 73 (11) p1341-6	*
	OAZ	KISSMEYER, AM; BINDERUP, E; BINDERUP, L; MORK, HANSEN C; ANDERSEN, NR; MAKIN, HL; SCHROEDER, NJ; SHANKAR, VN; JONES, G: "Metabolism of the Vitamin D Analog EB 1089: Identification of In Vivo and In Vitro Liver Metabolites and Their Biological Activities," <i>Biochem Pharmacol</i> (England) Apr 25 1997, 53 (8) p1087-97	*
	OBA	PAKKALA, I; SAVLI, H; KNUUTILA, S; BINDERUP, L; PAKKALA, S: "CB1093, a Novel Vitamin D Analog; Effects on Differentiation and Clonal Growth on HL-60 and de novo Leukemia Cells," <i>Leuk Res</i> (england) April 1997, 21 (4) p321-6	*
	OBb	de VOS, S; HOLDEN, S; HEBER, D; ELSTNER, E; BINDERUP, L; USKOKOVIC, M; RUDE, B; CHEN, DL; LE, J; CHO, SK; KOEFFLER, HP: "Effects of Potent Vitamin D <sub>3</sub> Analogs on Clonal Proliferation of Human Prostate Cancer Cell Lines," <i>Prostate</i> (United States), May 1, 1997, 31 (2) p77-83	*
	OBC	AKHTER, J; CHEN, X; BOWREY, P; BOLTON, EJ; MORRIS, DL: "Vitamin D <sub>3</sub> Analog, EB1089, Inhibits Growth of subcutaneous Xenografts of the Human Colon Cancer Cell Line, LoVo, in a Nude Mouse Model," <i>Dis Colon Rectum</i> (United States) March 1997, 40 (3) p317-21	*
MS	OBD	LAMARI, Y; GAREL, JM: "Decrease in CGRP and CT Levels Either contained in or Released by CA-77 C Cells After Combined Treatments with 1,25-dihydroxyvitamin D <sub>3</sub> Analogues and 9-cis Retinoic Acid," <i>Reprod Nutr Dev</i> (France) 1997, 37 (1) p3-12	*

\* only abstracts have been considered

Examiner Signature	Date Considered: 02/21/02
--------------------	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/804,111
				Filing Date	March 12, 2001
				First Named Inventor	Nongnuch Inpanbutr
				Group Art Unit	1645
				Examiner Name	
Sheet	9	of	18	Attorney Docket Number	06204-00102

MP	OBE	MUSIOL, IM; FELDMAN, D: "1,25-dihydroxyvitamin D <sub>3</sub> Induction of Nerve Growth Factor in L929 Mouse Fibroblasts: Effect of Vitamin D Receptor Regulation and Potency of Vitamin D <sub>3</sub> Analogs," <i>Endocrinology</i> (United States), Jan 1997, 138 (1) -12-8	
	OBF	JAMES, SY; MACKAY, AG; COLSTON, KW: "Effects of 1,25 Dihydroxyvitamin D <sub>3</sub> and Its Analogues on Induction of Apoptosis in Breast Cancer Cells," <i>J Steroid Biochem Mol Biol</i> (England), July 1996, 58 (4) p395-401	
	OBG	BAUDET, C; CHEVALIER, G; NAVEILHAN, P; BINDERUP, L; BRACHET, P; WION, D: "Cytotoxic Effects of 1 Alpha, 25-dihydroxyvitamin D <sub>3</sub> and Synthetic Vitamin D <sub>3</sub> Analogues on a Glioma Cell Line," <i>Cancer Lett</i> (Ireland), Feb 27 1996, 100 (1-2) p3-10	
	OBH	ROY, S; MARTEL, J; TENENHOUSE, HS: "Comparative Effects of 1,25-dihydroxyvitamin D <sub>3</sub> -24-hydroxylase," <i>J Bone Miner Res</i> (United States) Dec 1995, 10 (12) p1951-9	
	OBI	WIBERG, K; LJUNGHALL, S; BINDERUP, L; LJUNGGREN, O: "Studies on Two New Vitamin D Analogs, EB 1089 and KH 1060: Effects on Bone Resorption and Osteoclast Recruitment In Vitro," <i>Bone</i> (United States) Oct 1995, 17 (4) p391-5	
	OBJ	van den BEMD, GJ; POLS, HA; BIRKENHAGER, JC; KLEINEKOORT, WM; van LEEUWEN, JP: "Differential Effects of 1,25-dihydroxyvitamin D <sub>3</sub> -Analogues on Osteoblast-like Cells and on In Vitro Bone Resorption," <i>J Steroid Biochem Mol Biol</i> (England), Dec 1995, 55 (3-4) p337-46	
	OBK	DAVICCO, MJ; COXAM, V; GAUMET, N; LEBECQUE, P; BARLET, JP: "EB 1089, a Calcitriol Analogue, Decreases Fetal Calcium Content When Injected into Pregnant Rats," <i>Exp Physiol</i> (England), May 1995, 80 (3) p449-56	
MS	OBL	OKAMURA, WH; MIDLAND, MM; NORMAN, AW; HAMMOND, MW; DORMANEN, MC; NEMERE, I: "Biochemical Significance of the 6-s-cis Conformation of the Steroid Hormone 1 Alpha, 25-dihydroxyvitamin D <sub>3</sub> Based on the Provitamin D Skeleton," <i>Ann N Y Acad Sci</i> (United States) June 12 1995, 761 p344-8	

\* only abstracts have been considered


Examiner Signature		Date Considered:	02/21/02
--------------------	--	------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			Application Number	09/804,111
			Filing Date	March 12, 2001
			First Named Inventor	Nongnuch Inpanbutr
			Group Art Unit	1645
			Examiner Name	
Sheet 10 of 18	Attorney Docket Number 06204-00102			

MB	OBM	YU, J; PAPAVALIOU, V; RHIM, J; GOLTZMAN, D; KREMER, R: "Vitamin d Analogs: "New Therapeutic Agents for the Treatment of Squamous Cancer and its Associated Hypercalcemia," <i>Anticancer Drugs</i> (england), Feb 1995, 6 (1) p101-8	
	OBN	VINK-VAN WIJNGAARDEN, T; BIRKENHAGER, JC; KLEINEKOORT, WM; van den BEMD, GH; POLS, HA; van LEEUWEN, JP: "Antiestrogens Inhibit in Vitro Bone Resorption Stimulated by 1,25-dihydroxyvitamin D <sub>3</sub> and the vitamin D <sub>3</sub> Analogs," <i>Endocrinology</i> (United States) Feb 1995, 136 (2) p812-5	
	OBO	BERG, JP; LIANE, KM; BJORHOVDE, SB; BJORO, T; TORJESEN, PA; HAUG, E: "Vitamin D Receptor Binding and Biological Effects of Cholecalciferol Analogues in Rat Thyroid Cells," <i>J Steroid Biochem Mol Biol</i> (England) Aug 1994, 50 (3-4) p145-50	
	OBP	CARLBERG, C; MATHIASSEN, IS; SAURAT, JH; BINDERUP, L: "The 1,25-dihydroxyvitamin D <sub>3</sub> (VD) Analogues MC903, EB1089 and KH1060 Activate the VD Receptor: Homodimers Show Higher Ligand Sensitivity Than Heterodimers with Retinoid X Receptors," <i>J Steroid Biochem Mol Biol</i> (England), Nov 1994, 51 (3-4) p137-42	
	OBQ	HAQ, M; KREMER, R; GOLTZMAN, D; RABBANI, SA: "A Vitamin D Analogue (EB1089) Inhibits Parathyroid Hormone-related Peptide Production and Prevents the Development of Malignancy-Associated Hypercalcemia In Vivo," <i>J Clin Invest</i> (United States) June 1993, 91 (6) p2416-22	
	OBR	COLSTON, KW; MACKAY, AG; JAMES, SY; BINDERUP, L; CHANDER, S; COOMBES, RC: "A New Vitamin D Analogue that Inhibits the Growth of Breast Cancer Cells In Vivo and In Vitro," <i>Biochem Pharmacol</i> (England), Dec 15, 1992, 44 (12) p2273-80	
	OBS	LEE, YOUNG YIUL; PARK, WOO HYUN; SEOL, JAE GOO; KIM EUN, SHIL; HYUN, JUNG MI; SEOL, JAE GOO; KIM, EUN SHIL; HYUN, JUNG MI; JUNG, CHUL WON; LEE, CHUNG CHOO; KIM, BYOUNG KOOK: "Cell Cycle Arrest Induced by Vitamin D <sub>3</sub> Analog, EB1089, in NCI-H929 Myeloma Cells is Associated with Induction of Cyclin-dependent Kinase Inhibitor, p27," <i>Blood</i> 94 (10 SUPPL. 1 PART 2): p158b Nov. 15, 1999	
MA	OBT	LEE, YOUNG YIUL; PARK, WOO HYUN; SEOL, JAE GOO; KIM, EUN SHIL; HYUN, JUNG MI; JUNG, CHUL WON; LEE, CHUNG CHOO; KIM, BYOUNG KOOK: "Induction of Apoptosis by Vitamin D <sub>3</sub> Analog, EB1089, in NCI-H929 Myeloma Cells Via Activation of Caspase-3 and p38 Map Kinase," <i>Blood</i> 94 (10 SUPPL. 1 PART 2): p158b Nov. 15, 1999	

★ only abstracts have been considered

Examiner Signature	Date Considered: 02/24/02
--------------------	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/804,111
				Filing Date	March 12, 2001
				First Named Inventor	Nongnuch Inpanbutr
				Group Art Unit	1645
				Examiner Name	
Sheet	11	of	18	Attorney Docket Number	06204-00102

NB	OBV	XIE, SP; PIRIANOV, G; COSTON, KW: "Vitamin D Analogues Suppress IGF-I signalling and Promote Apoptosis in Breast Cancer Cells," <i>European Journal of Cancer</i> , 35 (12):p1717-1723 Nov., 1999	
	OBV	STENFELDT, MATHIASSEN IDA; LADEMANN, ULRIC; JAATTELA, MARJA: "Apoptosis Induced by Vitamin D Compounds in Breast Cancer Cells is Inhibited by Bcl-2 But does Not Involve Known Caspases or p53," <i>Cancer Research</i> 59 (19):p4848-4856 Oct. 1, 1999	
	OBW	LIN, R; AKUTSU, N; BASTIEN, Y; HENDERSON, JE; WHITE, JH: "Regulation of Vascular Endothelial Growth Factor Gene Expression by Vitamin D <sub>3</sub> ," <i>Journal of Bone and Mineral Research</i> , 14 (SUPPL. 1):pS424 Sept., 1999	
	OBX	NARAYANAN, R; SMITH, CL; WEIGEL, NL: "EB1089 Treatment Partially Reverses the Reduction in vitamin D Receptor Activity in MG-63 Cells Subjected to Simulated Microgravity," <i>Journal of bone and Mineral Research</i> 14 (SUPPL., 1):pS304 Sept., 1999	
	OBY	PETTERSSON, F; COLSTON, KW; DALGLEISH, AG: "Differential Control of Cell Growth and Death in Pancreatic Tumour Cells by Retinoids and Vitamin D Analogues," <i>British Journal of Cancer</i> 80 (SUPPL. 2):p48 July, 1999	
	OBZ	PIRIANOV, G; COLSTON, KW: "Vitamin D Analogues Suppress IGF-I Signalling and Promote Apoptosis in Human Breast Cancer Cells," <i>Journal of Endocrinology</i> 160 (SUPPL.):pOC3 March, 1999	
	OCA	LOKESHWAR, BAL L; SCHWARTZ, GARY G; SELZER, MARIE G; BURNSTEIN, KERRY L; ZHUANG, SEN-HONG; BLOCK, NORMAN L; BINDERUP, LISE: "Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,25-dihydroxyvitamin D (Calcitriol) and EB1089," <i>Cancer Epidemiology Biomarkers &amp; Prevention</i> 8 (3): p241-248	
	OCB	SUNDARAM, S; GEWIRTZ, DA: "tk;2EB 1089 Radiosensitizes Breast Tumor Cells," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 40p144-145 March, 1999	
NB	OCC	LEE, YY; SEOL, JG; PARK, WH; KIM, ES; JUNG, CW; BINDERUP, L; KOEFLER, HP; KIM, BK: "Vitamin D <sub>3</sub> Analog, EB1089, Induced Antileukemic Effect of HL-60 Cells Via Activation of Cyclin-Dependent Kinase Inhibitor, p21," <i>Blood</i> 92 (10 SUPPL. 1 PART 1-2):p204A Nov. 15, 1998	

★ only abstract have been considered

Examiner Signature	<i>[Signature]</i>	Date Considered:	6/21/02
--------------------	--------------------	------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			Application Number	09/804,111
			Filing Date	March 12, 2001
			First Named Inventor	Nongnuch Inpanbutr
			Group Art Unit	1645
			Examiner Name	
Sheet 12 of 18	Attorney Docket Number 06204-00102			

MB	OCD	DALHOFF, KIM; ASTRUP, LONE; BACH-HANSEN, JESPER; BURCHARTH, FLEMMING; HAAHR, HANNE LO; HAMBERG, KARIN J; EVANS, THOMAS RJ; LOFTS, FIONA; MOLLER, SUSANNE; RANEK, LEO; SKOVSGAARD, TORBEN; STEWARD, WILLIAM P: "Seocalcitol (EB1089), a Vitamin D Analogue, in Hepatocellular Carcinoma," <i>Hepatology</i> 28 (4 PART 2):p227A Oct., 1998	★
	OCE	KULLENBERG, B; AXELSON, J: "Analogues of Vitamin D <sub>3</sub> Decreases Stimulation of Growth by EGF and TGF-alpha in a Human Pancreatic Cancer Cell Line," <i>Digestion</i> 59 (3):p220-221 May-June, 1998	★
	OCF	DANIELSSON, CARINA; FEHSEL, KARIN; CARLBERG, CARSTEN: "Antiproliferative Response to Two Human Primary Melanoma Cell Lines to 1,25-dihydroxyvitamin D <sub>3</sub> and its Analogues," <i>Journal of Dermatological Science</i> , 16 (SUPPL. 1):pS102 March, 1998	★
	OCG	HUYNH, HUNG: "Regulation of Insulin-Like Growth Factor II (IGF-II) and IGF Binding Protein 3 Autocrine Loop in Human PC-3 Prostate Cancer Cells by 1,25(OH) <sub>2</sub> D <sub>3</sub> and its Analog BE1089," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 39p451 March, 1998	★
	OCH	SUNDARAM, S; GERWITZ, DA: "EB1089 Enhances the Antiproliferative Effects of Radiation in Breast Tumor Cells," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 39p5 March, 1998	★
	OCI	FALZON, MIRIAM; ZONG, JIAN: "The Noncalcemic Vitamin D Analogs FB1089 and 22-Oxacalcitriol Suppress Serum-induced parathyroid Hormone-related Peptide Gene Expression in a Lung Cancer Cell Line," <i>Endocrinology</i> , 139 (3):p1046-1053 March, 1998	★
	OCJ	PAKKALA, S; SPROGEL, P; REMES, K; NOUSIAINEN, T; KOIVUNEN, E; PELLINIEMI, T-T; RUUTU, T; ELONEN, E: EB1089, a Vitamin D Analog in MDS and AML, <i>Blood</i> 90 (10 SUPPL. 1 PART 1):p508A Nov. 15, 1997	★
MB	OCK	LEE, YY; PARK, WH; SEOL, JG; KIM, ES; JUNG, CW; BINDERUP, L; KOEFFLER, HP; KIM, BK: "In Vivo Effect of a Vitamin D <sub>3</sub> Analog, EB1089, on Acute Myelogenous Leukemia," <i>Blood</i> 90 (10 SUPPL. 1 PART 1):p189A Nov. 15, 1997	★

★ only abstracts have been considered

Examiner Signature		Date Considered: 6/21/02
--------------------	--	--------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>	
			Application Number	09/804,111
			Filing Date	March 12, 2001
			First Named Inventor	Nongnuch Inpanbutr
			Group Art Unit	1645
			Examiner Name	
Sheet 13 of 18	Attorney Docket Number 06204-00102			

WIP	OCL	SCHRADER, MAGDALENA; KAHLEN, JEAN-PIERRE; CARLBERG, CARSTEN: "Functional characterization of a Novel type of 1-Alpha, 25-Hydroxyvitamin D-3 Response Element Identified in the Mouse C-Fos Promoter," <i>Biochemical and Biophysical Research Communications</i> , 230 (3):p646-651 1997	☆
	OCM	KANE, KF; WALKER, EA; LANGMAN, MJS; WILLIAMS, GR: "Differential Activity of Vitamin Analogues Results From Altered Metabolism," <i>Journal of Endocrinology</i> , 151 (SUPPL.):pP98 1996	☆
	OCN	XIE, SP; JAMES, SY; COLSTON, KW: "Vitamin D Derivatives Inhibit the Mitogenic Effects of IGF-1 on Human Breast Cancer Cells," <i>Journal of Endocrinology</i> 151 (SUPPL.):pO30 1996	☆
	OCO	JAMES, SY; TURNER, A; COLSTON, KW: "Vitamin D Derivatives Potentiate the Induction of Apoptosis in Human Leukaemia Cells by Retinoids," <i>Journal of Endocrinology</i> 151 (SUPPL.):pO29 1996	☆
	OCP	PUTHIER, D; BATAILLE, R; BARILLE, S; MELLERIN, M-P; AMIOT, M: "Potent Cytostatic Effects of EB1089 a New Vitamin D-3 Derivative on Myeloma Cells," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 37(0):p392 1996	☆
	OCQ	WU, GF; SUN, LZ; BRATTAIN, MG: "Effects of 1,25(OH) <sub>2</sub> Vitamin D3 and its Analogues EB1089 on Regulation of TGF-beta Type II Receptor in Human Breast Cancer MCF-7 Cells," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 37 (0):p226 1996	☆
	OCR	GULLIFORD, T; ENGLISH, J; COLSTON, K; SPROGEL, P; COOMBES, RC: "A Phase 1 Study of EB1089, a Vitamin D Analogue," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 37(0):p164 1996	☆
	OCS	LOVE-SCHIMENTI, CD; GIBSON, DFC; BIKLE, DD: "Synergistic Antiproliferative Effects of Vitamin D-3 Analogs and Antiestrogens on ER= and ER- Breast Cancer Cell Lines," <i>Breast Cancer Research and Treatment</i> , 37 (SUPPL.):p72 1996	☆
MB	OCT	LEE, YY; KIM, ES; KIM, BK; KOEFFLER, HP: "Effect of a Vitamin D-3 Analog, EB1089, on Peripheral Blood Stem Cell Transplantation in AML," <i>Blood</i> 86 (10 SUPPL. 1):p143A 1995	☆

☆ only abstract have been considered

Examiner Signature:	Date Considered: 02/21/02
---------------------	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/804,111
				Filing Date	March 12, 2001
				First Named Inventor	Nongnuch Inpanbutr
				Group Art Unit	1645
				Examiner Name	
Sheet	14	of	18	Attorney Docket Number	06204-00102

MS	OCU	ARBELLE, JE; ADAMS, JS: "Vitamin D-induced CD14 Gene Expression in the Human Myelo-monocytic Cell Line U937: "Comparison of 1,25-dihydroxyvitamin D3 with Nonhypercalcemia-causing Analogs," <i>Journal of Investigative Medicine</i> , 43 (SUPPL. 2):p403A 1995	
	OCV	MILS, V; BASSET-SEGUIN, N; MOLES, JP; GUILHOU, JJ: "1,25(OH)2D3 and its Synthetic Derivatives (MC903 and EB1089) Induce a Partial Reversal of Tumoral Phenotype In Vitro," <i>Journal of Investigative Dermatology</i> 102(4):p642 1994	
	OCW	DE VOS, S; PAKKALA, S; ELSTNER, E; RUDE, B; USKOKOVIC, M; BINDERUP, L; KOEFFLER, HP: "Antileukemia Activity and In vivo Calcium-Studies of Several Novel Vitamin D-3 Analogs," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 35 (0):p408 1994	
	OCX	LUTZKY, J; VUJICIC, M; BINDERUP, L; BHALLA, K: "Vitamin D Analogs and Retinoids Exhibit Additive Cytotoxicity to Human Myeloma Cell Lines," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 35(0):p408 1994	
	OCY	SCHILLING, T; ALBRECHT, C; KOHL, B; ZIEGLER, R; RAUE, F: "Vitamin D and its New Analogue EB1089 in the Treatment of the Walker Carcinosarcoma 256, a Rat Model of Hypercalcemia of Malignancy," <i>Journal of Cancer Research and Clinical Oncology</i> 120 (SUPPL.):pR77 1994	
	OCZ	MACKAY, AG; JAMES, SY; OFORI-KURAGU, EA; BINDERUP, L; COLSTON, KW: "Down-regulation of the Oestrogen Receptor and Induction of Apoptosis in Breast Cancer Cells by EB1089, a Novel Vitamin D Analogue," <i>Journal of Endocrinology</i> 139 (SUPPL.):pP14 1993	
	ODA	PAKKALA, S; DEVOS, S; ELSTNER, E; RUDE, B; USKOKOVIC, M; BINDERUP, L; KOEFFLER, HP: "Antileukemic Activities and Effects on Serum Calcium of Three Novel Vitamin D-3 Analogs," <i>Blood</i> 82 (10 SUPPL. 1):p255A 1993	
MD	ODB	HAMADA, KATSUYUKI; SHINOMIYA, HIROTO: "Novel Vitamin D-3 Analogues and Their Potential for Inhibiting Cancer Cell Growth," <i>Drugs of the Future</i> 18 (11):p1057-1061 1993	

\* only abstract have been considered


Examiner Signature	Date Considered: 02/21/02
--------------------	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/804,111
				Filing Date	March 12, 2001
				First Named Inventor	Nongnuch Inpanbutr
				Group Art Unit	1645
				Examiner Name	
Sheet	15	of	18	Attorney Docket Number	06204-00102

	ODC	POSNER, GH; WANG, Q; HAH, G; JAE, KYOO LEE; CRAWFORD, K; ZAND, S; BREM, H; PELEG, S; DOLAN, P; KENSLER, TW: "Conceptually New Sulfone Analogues of the Hormone Lalpha, 25-dihydroxyvitamin Dinf 3: Synthesis and Preliminary Biological Evaluation," <i>Journal of Medicinal Chemistry</i> (J. MED. CHEM.) (United States) 09 SEP 1999, 42/18 (3425-3435)	
	ODD	KOSHIZUKA, K; KUBOTA, T; SAID, J; KOIKE, M; BINDERUP, L; USKOKOVIC, M; KOEFFLER, HP: "Combination Therapy of a Vitamin Dinf 3 Analog and All-trans-retinoic Acid: Effect on Human Breast Cancer in Nude Mice," <i>Anticancer Research</i> (ANTICANCER RES.) (GREECE) 1999, 19/1 A (519-524)	
	ODE	KOSHIZUKA, K; KOIKE, M; ASOU, H; CHO, SK; STEPHEN, T; RUDE, RK; BINDERUP, L; USKOKOVIC, M; KOEFFLER, HP: "Combined Effect of Vitamin Dinf 3 Analogs and Paclitaxel on the Growth of MCF-7 Breast Cancer Cells In Vivo," <i>Breast Cancer Research and Treatment</i> (BREAST CANCER RES. TREAT.) (United States) 1999, 53/2 (113-120)	
	ODF	VAN WEELDEN, K; FLANAGAN, L; BINDERUP, L; TENNISWOOD, M; WELSH, J: "Apoptotic Regression of MCF-7 Xenografts in Nude Mice Treated with the Vitamin Dinf 3 Analog, EB1089," <i>Endocrinology</i> (United States) 1998, 139/4 (2102-2110)	
	ODG	JONES, G; STRUGNELL, SA; DELUCA, HF: "Current Understanding of the Molecular Actions of Vitamin D," <i>Physiological Reviews</i> (Physiol. Rev.) (United States) 1998, 78/4 (1193-1231)	
	ODH	DANIELSSON, C; MATHIASSEN, IS; JAMES, SY; NAYERI, S; BRETTING, C; HANSEN, CM; COLSTON, KW; CARLBERG, C: "Sensitive Induction of Apoptosis in Breast Cancer Cells by a Novel 1,25-dihydroxyvitamin Dinf 3 Analogue Shows Relation to Promoter Selectivity," <i>Journal of Cellular Biochemistry</i> (J. CELL. BIOCHEM.) (United States) 1997, 66/4 (552-562)	
	ODI	NALDI, L: "Psoriasis: Latest Advances in Understanding and Nove Therapeutic Approaches. 12-13 May, 1997, London, UK," <i>Expert Opinion on Investigational Drugs</i> (EXPERT OPIN. INVEST. DRUGS) (United Kingdom) 1997, 6/7 (895-898)	
	ODJ	SCHRADER, M; KAHLEN, JP; CARLBERG, C: "Functional Characterization of a Novel Type of Lalpha, 25-dihydroxyvitamin Dinf 3 Response Element Identified in the Mouse c-fos Promoter," <i>Biochemical and Biophysical Research Communications</i> (BIOCHEM. BIOPHYS. RES. COMMUN.) (United States) 1997, 230/3 (646-651)	

*only ABSTRACTS have been considered*

Examiner Signature		Date Considered:	02/21
--------------------	--	------------------	-------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →

☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/804,111
				Filing Date	March 12, 2001
				First Named Inventor	Nongnuch Inpanbutr
				Group Art Unit	1645
				Examiner Name	
Sheet	16	of	18	Attorney Docket Number	06204-00102

MD	ODK	DE VOS, S; HOLDEN, S; HEBER, D; ELSTNER, E; BINDERUP, L; USKOKOVIC, M; RUDE, B; CHEN, DL; LE, J; CHO, SK; KOEFFLER, HP: "Effects of Potent Vitamin Dinf 3 Analogs on Clonal Proliferation of Human Prostate Cancer Cell Lines," <i>Prostate</i> (PROSTATE) (UNITED STATES) 1997, 31/2 (77-83) *	
	ODL	LAMARI, Y; GAREL, JM: "Decrease in CGRP and CT Levels Either Contained in or Released by CA-77 C Cells After Combined Treatments with 1,25-dihydroxyvitamin Dinf 3 Analogues and 9-cis Retinoic Acid," <i>Reproduction Nutrition Development</i> (REPROD. NUTR. DEV.) (France) 1997 37/1 (3-12) *	
	ODM	AKHTER, J; CHEN, X; BOWREY, P; BOLTON, EF; MORRIS, DL: "Vitamin Dinf 3 Analog, EB1089, Inhibits Growth of Subcutaneous Xenografts of the Human Colon Cancer Cell Line, LoVo, in a Nude Mouse Model," <i>Diseases of the Colon and Rectum</i> (DIS.COLON RECTUM) (United States) 1997, 40/3 (317-321) *	
	ODN	MACKAY, AG; OFORI-KURAGU, EA; LANSDOWN, A; COOMBES, RC; BINDERUP, L; COLSTON, KW: "Effects of the Synthetic Vitamin D Analogue EB1089 and Tamoxifen on the Growth of Experimental Rat Mammary Tumours," <i>Endocrine-Related Cancer</i> (ENDOCR.-RELAT.CANCER) (United Kingdom) 1996 3/4 (327-335) *	
	ODO	MUSIOL, IM; FELDMAN, D: "1,25-dihydroxyvitamin Dinf 3 Induction of Nerve Growth Factor in L929 Mouse Fibroblasts: Effect of Vitamin D Receptor Regulation and Potency of Vitamin Dinf 3 Analogs," <i>Endocrinology</i> (ENDOCRINOLOGY) (United States) 1997, 138/1 (12-18) *	
	ODP	JAMES, SY; MACKAY, AG; COLSTON, KW: "Effects of 1,25 Dihydroxyvitamin Dinf 3 and its Analogues on Induction of Apoptosis in Breast Cancer Cells," <i>Journal of Steroid Biochemistry and Molecular Biology</i> (J. STEROID BIOCHEM. MOL. BIOL.) (United Kingdom) 1996, 58/4 (395-401) *	
	ODQ	BAUDET, C; CHEVALIER, G; NAVEILHAN, P; BINDERUP, L; BRACHET, P; WION, D: "Cytotoxic Effects of Lalpha, 25-dihydroxyvitamin Dinf 3 and Synthetic Vitamin Dinf 3 Analogues on a Glioma Cell Line," <i>Cancer Letters</i> (CANCER LETT.) (Ireland) 1996, 100/- (3-10) *	
NR	ODR	VAN DEN BEMD, GJCM; POLS, HAP; BIRKENHAGER, JC; KLEINEKOORT, WMC; VAN LEEUWEN, JPTM: "Differential Effects of 1,25-dihydroxyvitamin Dinf 3-analogs on Osteoblast-like Cells and on In Vitro Bone Resorption," <i>Journal of Steroid Biochemistry and Molecular Biology</i> (J. STEROID BIOCHEM. MOL. BIOL.) (United Kingdom) 1995, 55/3-4 (336-346) *	

\* only abstracts

Examiner Signature		Date Considered: 02/21/02
--------------------	--	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/804,111
Filing Date	March 12, 2001
First Named Inventor	Nongnuch Inpanbutr
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	06204-00102

Sheet 17 of 18

MA	ODS	ROY, S; MARTEL, J; TENENHOUSE, HS: "Comparative Effects of 1,25-dihydroxyvitamin Dinf 3 and EB1089 on Mouse Renal and Intestinal 25-hydroxyvitamin Dinf 3-24-hydroxylase," <i>Journal of Bone and Mineral Research</i> (J. BONE MINER. RES.) (United States) 1995, 10/12 (1951-1959)	☆
	ODT	KISSMEYER, AM; MATHIASSEN, IS; LATINI, S; BINDERUP, L: "Pharmacokinetic Studies of Vitamin D Analogues: Relationship to Vitamin D Binding Protein (DBP)," <i>Endocrine</i> (ENDOCRINE) (United Kingdom) 1995, 3/4 (263-266)	☆
	ODU	WIJNGAARDEN, TVV; BIRKENHAGER, JC; KLEINEKOORT, WMC; VAN DEN BEMD, GJCM; POLS, HAP; VAN LEEUWEN, JPTM: "Antiestrogens Inhibit in vitro Bone Resorption Stimulated by 1,25-dihydroxyvitamin Dinf 3 and the Vitamin Dinf 3 Analogs EB1089 and KH1060," <i>Endocrinology</i> (Endocrinology)(UNITED STATES) 1995, 136/2 (812-815)	☆
	ODV	PAKKALA, S; DE VOS, S; ELSTNER, E; RUDE, RK; USKOKOVIC, M; BINDERUP, L; KOEFFLER, HP: "Vitamin Dinf 3 Analogs: Effect on Leukemic Clonal Growth and Differentiation, and on Serum Calcium Levels," <i>Leukemia Research</i> (LEUK.RES.) (United Kingdom) 1995, 19/1 (65-72)	☆
	ODW	CARLBERG, C; MATHIASSEN, LIS; SAURAT, J; BINDERUP, L: "The 1,25-dihydroxyvitamin Dinf 3 (VD) Analogues MC903, EB1089 and KH1060 Activate the VD Receptor: Homodimers Show Higher Ligand Sensitivity Than Heterodimers with Retinoid X Receptors," <i>Journal of Steroid Biochemistry and Molecular Biology</i> (J. STEROID BIOCHEM. MOL. BIOL.) (United Kingdom) 1994, 51/3-4 (137-142)	☆
	ODX	HAMADA, K; SHINOMIYA, H: "Novel Vitamin Dinf 3 Analogs and Their Potential for Inhibiting Cancer Cell Growth," <i>Drugs of the Future</i> (DRUGS FUTURE) (Spain) 1993, 18/11 (1057-1061)	☆
	ODY	KOLI, K; KESKI-OJA: "Vitamin Dinf 3 and Calcipotriol Decrease Extracellular Plasminogen Activator Activity in Cultured Keratinocytes," <i>Journal of Investigative Dermatology</i> (J. INVEST. DERMATOL.) (United States) 1993, 101/5 (706-712)	☆
MD	ODZ	BINDERUP, L: "Vitamin D Analogues: New Regulators of Cancer Cell Growth and Differentiation," <i>Bioorganic and Medicinal Chemistry Letters</i> (BIOORG. MED. CHEM. LETT.) (United Kingdom) 1993, 3/9 (1891-1896)	☆

☆ Abstract only

Examiner Signature		Date Considered: 02/21/02
--------------------	--	---------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please Type a plus sign (+) inside this box →



PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Compl t if Known</b>	
				Application Number	09/804,111
				Filing Date	March 12, 2001
				First Named Inventor	Nongnuch Inpanbutr
				Group Art Unit	1645
Examiner Name					
Sheet	18	of	18	Attorney Docket Number	06204-00102

NR	OE A	HAQ, M; KREMER, R; GOLTZMAN, D; RABBANI, SA: "A Vitamin-D Analog (EB1089) Inhibits parathyroid-Hormone Related Peptide Production and Prevents the Development of Malignancy-Associated Hypercalcemia In vivo," <i>Journal of Clinical Investigation</i> , 1993, V91, N6 (JUN), P2416-2422	
W3	OE B	KABANOS, TA; WHITE, AJP; WILLIAMS, DJ; WOOLLINS, JD: "Synthesis and X-Ray Structures of Bis(3,5-di-tert-butylcatecholato)(phenanthroline)vanadium (iv) and its Vanadium (v)," <i>Journal of the chemical Society - Series Chemical Communications (J. CHEM. SOC. SER. CHEM. COMMUN.)</i> (United Kingdom) 1992, -1/ (17-18)	

*\* abstracts only*

Examiner Signature		Date Considered:	02/21/02
--------------------	--	------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WSIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.